← Leaderboards
Agnieszka Witkiewicz
Thomas Jefferson University
$7,548,076
Attributed
$11,881,052
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,881,052 · 9
By mechanism
R01$10,287,449 · 5
P30$1,298,603 · 3
S10$295,000 · 1
Top collaborators
- Erik Knudsen20 shared
Most similar at Thomas Jefferson University
Same institution · by research overlap
- Erik Debler$3,254,531
- Antonio Giordano$4,608,769
- Mark A Feitelson$9,601,309
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorMalignant NeoplasmsResponsePathway InteractionsResistanceCdk4 GeneTissuesMalignant Breast NeoplasmTargeted TreatmentCell CycleSpecimenComplexPre-Clinical ModelTherapy ResistantDisease ProgressionBiologicalGeneticTherapeutic TargetCell Cycle RegulationEventEvolutionProgramsPublishingTumor Suppressor Proteins
Grant awards (34)
Delineating the dystopian nature of the cell cycle in cancer$534,959
R01 · FY2025 · CA
Impact of RB activation on the pancreatic cancer epigenome and tumor microenvironment$505,216
R01 · FY2025 · CA · contact PI
Delineating the dystopian nature of the cell cycle in cancer$513,684
R01 · FY2024 · CA
Impact of RB activation on the pancreatic cancer epigenome and tumor microenvironment$479,955
R01 · FY2024 · CA · contact PI
RB tumor suppressor as a therapeutic target in ER-positive breast cancer$408,055
R01 · FY2024 · CA
RB tumor suppressor as a therapeutic target in ER-positive breast cancer$316,204
R01 · FY2024 · CA
Delineating the dystopian nature of the cell cycle in cancer$538,372
R01 · FY2023 · CA
Impact of RB activation on the pancreatic cancer epigenome and tumor microenvironment$505,216
R01 · FY2023 · CA · contact PI
RB tumor suppressor as a therapeutic target in ER-positive breast cancer$420,941
R01 · FY2023 · CA
RB tumor suppressor as a therapeutic target in ER-positive breast cancer$351,338
R01 · FY2023 · CA
Delineating the dystopian nature of the cell cycle in cancer$549,360
R01 · FY2022 · CA
RB tumor suppressor as a therapeutic target in ER-positive breast cancer$420,941
R01 · FY2022 · CA
RB tumor suppressor as a therapeutic target in ER-positive breast cancer$351,338
R01 · FY2022 · CA
RB tumor suppressor as a therapeutic target in ER-positive breast cancer$429,531
R01 · FY2021 · CA
Common Genetically Altered Pathways as Targets for Therapy in Pancreatic Cancer$392,993
R01 · FY2021 · CA · contact PI
Digital Spatial Profiler$295,000
S10 · FY2021 · OD · contact PI
Pathology Network Shared Resource$275,153
P30 · FY2021 · CA · contact PI
Genetics and Genomics$45,965
P30 · FY2021 · CA · contact PI
RB tumor suppressor as a therapeutic target in ER-positive breast cancer$429,531
R01 · FY2020 · CA
Common Genetically Altered Pathways as Targets for Therapy in Pancreatic Cancer$392,993
R01 · FY2020 · CA · contact PI
Pathology Network Shared Resource$275,153
P30 · FY2020 · CA · contact PI
Common Genetically Altered Pathways as Targets for Therapy in Pancreatic Cancer$381,202
R01 · FY2019 · CA · contact PI
Pathology Network Shared Resource$275,153
P30 · FY2019 · CA · contact PI
Common Genetically Altered Pathways as Targets for Therapy in Pancreatic Cancer$392,993
R01 · FY2018 · CA · contact PI
Common genetically altered pathways as targets for therapy in pancreatic cancer$351,131
R01 · FY2017 · CA · contact PI
Impact of ErbB2 and RB Pathways on DCIS Progression and Treatment$327,957
R01 · FY2016 · CA · contact PI
Impact of ErbB2 and RB Pathways on DCIS Progression and Treatment$326,689
R01 · FY2015 · CA · contact PI
Impact of ErbB2 and RB Pathways on DCIS Progression and Treatment$317,256
R01 · FY2014 · CA · contact PI
Impact of ErbB2 and RB Pathways on DCIS Progression and Treatment$310,118
R01 · FY2013 · CA · contact PI
Impact of ErbB2 and RB Pathways on DCIS Progression and Treatment$330,513
R01 · FY2012 · CA · contact PI
Translational Research$137,271
P30 · FY2012 · CA · contact PI
Impact of ErbB2 and RB Pathways on DCIS Progression and Treatment$8,963
R01 · FY2012 · CA · contact PI
Translational Research$140,765
P30 · FY2011 · CA · contact PI
Translational Research$149,143
P30 · FY2010 · CA · contact PI